CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to ...
Goldman Sachs' Terence Flynn upgraded Acceleron from Sell to Neutral with a price target lifted from $21 to $40. Flynn named the following reasons for investors to be incrementally optimistic on ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics ...
Merck spent a small fortune on the acquisition of Acceleron Pharma, and so far, it's paying off. Recent phase 2 data suggests the pharmaceutical giant could get even more bang for its buck. Despite ...
Merck will spend about $11.5 billion to buy Acceleron Pharma and its potential treatment for high blood pressure in vessels that connect the lungs and heart. Merck will pay $180 per share in cash for ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Acceleron Pharma Inc. in Cambridge said collaborators at ...
Shares of Acceleron Pharma Inc., which is developing therapies for cancer and rare diseases, rose by one-third in its first day of trading Thursday. Shares closed up $4.99, or 33%, at $19.99.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results